Introduction
Fanconi anemia (FA) is an autosomal recessive disease characterized by developmental abnormalities, bone marrow failure, and cancer susceptibility (1, 2) . The mean survival of FA pa-subtype of the remaining patients, we generated retroviral constructs expressing FAA and FAC for transduction of FA cell lines (pMMP-FAA and pMMP-FAC). The pMMP-FAA construct specifically complemented the abnormal phenotype of cell lines from FA-A patients, while pMMP-FAC complemented FA-C cells. In summary, the combination of immunoblot analysis and retroviral-mediated phenotypic correction of FA cells allows a rapid method of FA subtyping.
tients is 16 years, and death usually results from complications of bone marrow failure (3) . The preferred treatment for bone marrow failure in FA is HLA-matched related allogeneic bone marrow transplantation. Transplantation can result in long-term marrow recovery, but most FA patients do not have matched donors (4) (5) (6) . Gene therapy (7) , using one of the two cloned FA cDNAs (FAA and FAC) (8) (9) (10) , offers an alternative strategy for FA treatment, but it requires prior knowledge of the patient's complementation group. Functional retroviruses for the FAA cDNA ( 11) and the FAC cDNA (7) have recently been described.
Diagnosis of FA exploits the sensitivity of FA cells to the bifunctional alkylating agents mitomycin C (MMC) and diepoxybutane (DEB). Analysis of DEB-induced chromosomal breakage provides a highly sensitive and specific diagnostic test for new patient and prenatal screening (12) (13) (14) (15) , but it does not distinguish among the known complementation groups of FA. Screening methods have been developed for the relatively small number of FAC mutant alleles, allowing identification of the great majority of FA-C patients (16, 17) . In contrast, the FAA gene has a large number of different mutant alleles that have been described, rendering genotypic analysis less practical for screening new FA patients (9, 10, 18) .
Definitive complementation group subtyping of FA patients has traditionally involved somatic cell fusion studies of patient cells with index cells of known complementation groups (19) (20) (21) . These studies allowed the identification of at least eight complementation groups of FA (19) (20) (21) , leading to the cloning of the FAA and FAC genes (8) (9) (10) and to the mapping of the FAD gene (22) . FA-A and FA-C account for approximately 66% and 13% of FA patients, respectively (19) (20) (21) . Since subtyping by somatic cell fusion is generally slow and laborious, newer approaches using the cloned FA genes would be advantageous.
In the current study, we used a combination of immunoblot analysis, with newly available anti-FAA and anti-FAC antisera, and retroviral infection to confirm the subtype of 26 FA (27) (a generous gift of Takara Shuzo Co., Japan). Concentrated retroviral supernatants (0.1 ml) were added to 1 X 106 lymphoblasts in 0.4 ml of RPMI plus 15% FCS for [6] [7] [8] [9] [10] [11] [12] hr in the presence of 4 ,ug/ml polybrene. After hr, cells were analyzed for MMC sensitivity or FAA protein expression.
Titering of Retroviral Supernatants Supernatants were titered by adding retroviral supernatant (1 ml) to NIH-3T3 cells (3 X 105) in the presence of polybrene (8 ,ug/ml). The medium was changed after 4 hr, and the cells were grown to confluence. Cells were trypsinized and DNA isolated by the Puregene DNA isolation kit (Gentron). DNA (10 ,ug) from each sample was run on 0.7% agarose gels alongside several lanes with control DNA spiked with plasmid amounts equivalent to known copy numbers. DNA was then transferred to a duralon membrane and UV cross-linked. The blot was probed with a 32p_ labeled fragment (588 bp) generated by PCR from the FAA cDNA. Blots were scanned with the GS-525 Molecular Imaging System and quantitated by Molecular Analysis Software (BioRad, Hercules, CA).
Mitomycin C Assay MMC sensitivity assays on lymphoblasts were performed as previously described (23, 28) . MMC sensitivity assays for fibroblasts were performed by the G2 accumulation assay (see below).
Immunoblot Analysis For immunoblotting, proteins from whole cell extracts were run on SDS-PAGE and transferred to nitrocellulose in transfer buffer (Tris 25 mM, glycine 200 mM) at 400 mA at 4°C. Filters were blocked for 1 hr in 5 % bovine serum albumin (BSA) in TBS (50 mM Tris-HCl, pH 8.0, 150 mM NaCl) and incubated in primary antibody (either N-terminal-or C-terminal-specific anti-FAA antisera or an N-terminal-specific anti-FAC antiserum) in TBS plus 0.1% Tween 20 (TBS-T) at room temperature for 12 hr. These polyclonal antibodies were purified from rabbit serum after injecting HA-tagged amino-and carboxy-terminal sequences of FAA and FAC proteins and were shown to have specificity for FAA and FAC proteins compared with preimmune serum (23, 29) . After extensive washing in TBS-T and exposure to horseradish peroxidase-protein A, enzyme-linked chemiluminescence (Amersham) was performed.
Assay for Correction of G2 Accumulation Forty-eight hours after retroviral transduction of primary fibroblasts, MMC (25 ng/ml) was added to the culture dishes. Cells were cultured for an additional 48 hr in MMC and correction of MMC sensitivity was assessed by the G2 accumulation assay (28) . Briefly, cells were trypsinized, washed once in PBS, and resuspended in PBS (1 ml (33, 34) (Fig. 4 ). An FA-A fibroblast line (PD320) accumulated to 59% in G2/M, after exposure to MMC (Fig. 4B) . These same cells, infected with pMMP-FAA, accumulated to only 25% G2/M after MMC exposure (Fig. 4C) , thereby demonstrating their functional complementation by FAA expression. Cells infected with pMMP-FAC or pMMP-nlsLacZ remained MMC sensitive, with G2/M accumulations of 51% and 56%, respectively (Fig. 4D, E) .
We next analyzed MMC-induced G2/M accumulation of five FA primary fibroblast cultures, after infection with either pMMP-FAA, pMMP-FAC, or pMMP-nlsLacZ retroviral supernatants (Fig. 5) FAC retrovirus, all were corrected to MMC resistance. Infection with FAA and FAC virus had no effect on the MMC sensitivity of the two lymphoblast FA-D cell lines (Table 1) or control cell lines derived from normal volunteers (data not shown). These results are in accordance with the immunoblot data summarized in Table 1 and further confirm previous complementation group assignment. The EUFA007 cell line is particularly interesting (Table 1, Fig. IA, lane 14) . These cells are compound heterozygotes for the FAA gene (H. Joenje, personal communication) and contain the mutant FAA allele 3788-3790del, which accounts for 5% of known FAA mutations (18 (Fig. 2) . Accordingly, the diagnosis of FA-A or FA-C can be accomplished in most cases by immunoblot analysis alone. Immunoblot analysis should be subsequently confirmed by retroviral infection of lymphoblast lines or primary skin fibroblasts, followed by MMC sensitivity assays.
Subtyping by immunoblot analysis is particularly advantageous for patients with FA-A, which accounts for approximately 66% of FA cases (20) . Unlike FA-C, where only six mutant alleles account for most patients (16, 17) , numerous FA-A mutant alleles have been identified (18) . Most FAA gene mutations known to date (9,10) result from internal deletions or truncations of genomic segments. As mentioned above, most FA-A cell lines (13/16) 
